The emphasis of clinical practice is slowly shifting from one-disease and one-treatment-fits-all to more personalized care based on molecular markers of disease risk, disease subtype, drug effectiveness, and adverse drug reactions. Through the use of case studies, this course will review the genetic, genomic, proteomic, and metabolomic technologies being applied for biomarker discovery and molecular diagnostic development. The emerging role of the FDA in personalized medicine will be addressed. The economic impact and ethical issues arising from this next generation of diagnostics will also be discussed. The class is designed as a survey course and is appropriate for researchers and individuals in the business of biotechnology who possess a basic science background.
Course Number: BIOL-40251
Credit: 3.00 unit(s)